Brand Your Generic or Watch Competitors Own Your Market: The Data-Driven Decision Framework
The question sounds deceptively simple: should you put a brand name on your generic drug? In practice, it is one […]
Pharmaceutical Patent Pools: The Strategic Playbook Every Originator and Generic Needs Now
The conventional view of a pharmaceutical patent is simple: it is a monopoly right, a wall built to keep competitors
Small Molecules: The Pharmaceutical Industry’s Most Durable Strategic Asset
The pharmaceutical industry has spent much of the past decade performing a kind of collective memory erasure about small molecules.
Small Molecules: The Pharmaceutical Industry’s Most Durable Strategic Asset Read Post »
Paragraph IV Challenges: The Global Playbook for Generic Entry, Patent Wars, and the 180-Day Prize
A reference-grade guide for generic drug IP teams, litigation counsel, portfolio managers, business development executives, and institutional investors who need
Stop Siloing Your Data: The Pharma Intelligence Framework That Actually Predicts Winners
How integrating patent, clinical, and scientific data into a single intelligence engine is replacing guesswork in life sciences strategy—and what
Stop Siloing Your Data: The Pharma Intelligence Framework That Actually Predicts Winners Read Post »
Stop Racing to the Bottom: The Generic Drug Strategy That Builds Real Competitive Advantage
How patent intelligence, regulatory mastery, and manufacturing technology are separating the winners from the commoditized in a $700 billion market
Compounding Pharmacies vs. Drug Patents: The Complete IP Battleground Guide for Pharma Strategists
A technical deep-dive for IP counsel, 503B portfolio managers, brand lifecycle teams, and institutional investors tracking the $10.93B compounding market.
Method-of-Use Patents: The Definitive Analyst’s Guide to the New Front Line in Generic Drug Litigation, IP Valuation, and Strategic Defense
1. Why Method-of-Use Patents Now Control More Revenue Than Compound Patents A structural shift has occurred in pharmaceutical patent litigation
Generic Drug Patent Disputes: The Complete Analyst’s Guide to Paragraph IV Challenges, Patent Thickets, and Hatch-Waxman Litigation Strategy
I. Executive Summary The U.S. pharmaceutical patent system is not a passive legal framework. It is an engineered adversarial machine,
